Pharmacyclics Revenue and Competitors
Estimated Revenue & Valuation
- Pharmacyclics's estimated annual revenue is currently $750M per year.
- Pharmacyclics's estimated revenue per employee is $961,538
- Pharmacyclics's total funding is $14.5M.
Employee Data
- Pharmacyclics has 780 Employees.
- Pharmacyclics grew their employee count by -1% last year.
Pharmacyclics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Quality & Technical Operations | Reveal Email/Phone |
2 | Head Human Resources | Reveal Email/Phone |
3 | Associate Director, Drug Product, Process and Equipment Engineering | Reveal Email/Phone |
4 | Associate Director, Alliance Management | Reveal Email/Phone |
5 | Associate Director | Reveal Email/Phone |
6 | Assistant Scientific Director, Scientific Medical Affairs | Reveal Email/Phone |
7 | Senior Director, Bioinformatics | Reveal Email/Phone |
8 | Director, Trade & Federal Markets at Pharmacyclics | Reveal Email/Phone |
9 | Associate Director, Clinical Operations | Reveal Email/Phone |
10 | Senior Senior Director, Enterprise Applications & Analytics | Reveal Email/Phone |
Pharmacyclics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Pharmacyclics?
Pharmacyclics is a pharmaceutical company developing novel agents to improve current therapeutic approaches to cancer, cardiovascular diseases, and inflammation. The company’s products are rationally designed, ring-shaped small molecules called texaphyrins. Texaphyrins selectively concentrate in diseased tissue, such as tumor cells and vulnerable plaque. They disrupt the bioenergetic processes of these cells, and when combined with other treatment modalities or various forms of energy, such as chemotherapy, radiation or light, apoptosis (programmed cell death) of the diseased tissue occurs. In this manner, texaphyrins can help to reduce or eliminate the diseased tissue
keywords:N/A
$14.5M
Total Funding
780
Number of Employees
$750M
Revenue (est)
-1%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Pharmacyclics News
AbbVie (Pharmacyclics), Johnson & Johnson (Janssen Biotech), SP Laboratories. The Global Imbruvica Market Report includes the top companies...
Prior research with ibrutinib [Imbruvica; Pharmacyclics, Janssen] had shown that patients with chronic lymphocytic leukemia and immune...
AstraZeneca and Pharmacyclics enter clinical trial collaborations in oncology 04-11-2014 Studies planned to evaluate IMBRUVICA® in combination with AstraZeneca investigational therapies for the treatment of solid tumours and haematological cancers AstraZeneca and Pharmacyclics, Inc. today ann ...
AstraZeneca and Pharmacyclics enter clinical trial collaborations in oncology 04-11-2014 Studies planned to evaluate IMBRUVICA® in combination with AstraZeneca investigational therapies for the treatment of solid tumours and haematological cancers AstraZeneca and Pharmacyclics, Inc. today ann ...
Other Companies in Sunnyvale
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $169.1M | 833 | N/A | N/A |
#2 | $409.2M | 835 | 3% | N/A |
#3 | $171.2M | 855 | -5% | $496M |
#4 | $300M | 890 | 0% | N/A |
#5 | $310.8M | 906 | 5% | N/A |